Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007
06 mars 2020 08h01 HE
|
Seelos Therapeutics, Inc.
NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics to Participate in Two Upcoming Investor Conferences in March
19 févr. 2020 08h02 HE
|
Seelos Therapeutics, Inc.
Cowen 40th Annual Health Care Conference on March 2nd-4th in Boston, MARoth Capital 32nd Annual Conference on March 16th-17th in Laguna Niguel, CA NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) --...
Seelos Therapeutics Announces Closing of Public Offering of Common Stock
13 févr. 2020 16h30 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock
10 févr. 2020 20h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007
28 janv. 2020 08h02 HE
|
Seelos Therapeutics, Inc.
Delivery of SLS-007 to Utilize an Adeno-Associated Virus (AAV) VectorSLS-007 to Become Seelos’ Second Gene Therapy Program Focused on Parkinson’s NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Seelos...
Seelos Therapeutics to Participate in Upcoming Investor Conferences in December
01 nov. 2019 10h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Evercore ISI 2nd...
Seelos Therapeutics to Participate in Upcoming Investor Conference in November
18 oct. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Jefferies 2019...
Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant
15 oct. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today announced the addition of Scott Applebaum to its team as lead...
Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering
23 août 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase...
Seelos Therapeutics to Ring Opening Bell at Nasdaq on August 12th
06 août 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that Raj Mehra, PhD, Chairman, Founder, and CEO of...